Results 181 to 190 of about 509,471 (220)

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck   +12 more
wiley   +1 more source

Retraction notice to "Targeted teaching method combined with stepped assessment in public tennis lessons" [Heliyon 9 (2023) e16680]. [PDF]

Heliyon
Huang P, Saibon JB, Xue Y.
europepmc   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source

RETRACTION: The Role of Orthobiologics in Chronic Wound Healing. [PDF]

Int Wound J
europepmc   +1 more source

Shifting Values and Shifting Risks: Debates on the New Biology in Germany and the United States Before and After Asilomar (1960-1980). [PDF]

J Hist Biol
Brandt C.
europepmc   +1 more source

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

Molecular Oncology, EarlyView.
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto, Louise Raunkilde, Jan Lindebjerg, Mads Malik Aagaard, Christina Therkildsen, Jakob Kleif, Lars Henrik Jensen, Torben Frøstrup Hansen, Rikke Fredslund Andersen   +8 more
wiley   +1 more source

Streamlining a Patchwork - Exploring the Challenges of Digital Transformation in Pathology: Ethnographic Study.

J Med Internet Res
Geisler BL, Amperidou O, Pauly SP, Mattern S, Schürch CM, Hermann C, Stoffregen C, Steinleitner I, Paigin N, Lamß C, Fend F, Rieger MA, Rind E, Preiser C.   +13 more
europepmc   +1 more source

What Community Members With Chronic Illness Teach Future Healthcare Professionals in a Longitudinal Interprofessional Education Program: A Focus Group Study. [PDF]

Clin Teach
White R, Brucato M, King A, Mitchell AB, Ankam NS.   +4 more
europepmc   +1 more source

Perspectives in educating molecular pathologists on liquid biopsy: Toward integrative, equitable, and decentralized precision oncology

Molecular Oncology, EarlyView.
Liquid biopsy enables minimally invasive, real‐time molecular profiling through analysis of circulating biomarkers in biological fluids. This Perspective highlights the importance of training pathologists through integrative educational programs, such as the European Masters in Molecular Pathology, to ensure effective and equitable implementation of ...
Marius Ilié, Umberto Malapelle, Catherine Alix‐Panabières, Claus Lindbjerg Andersen, Sandra Chlebowski, Vivien Lake, Caroline Lacoux, Virginie Lespinet‐Fabre, Olivier Bordone, Simon Heeke, Christophe Bontoux, Ellen Heitzer, Klaus Pantel, Paul Hofman   +13 more
wiley   +1 more source

Reply to Pagnoni et al. Clarifying the Clinical Utility of NTAR/RGR for PAH and CTEPH. Comment on "Iancu et al. Evaluating NT-proBNP-to-Albumin (NTAR) and RDW-to-eGFR (RGR) Ratios as Biomarkers for Predicting Hospitalization Duration and Mortality in Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH). <i>Diagnostics</i> 2025, <i>15</i>, 2126". [PDF]

Diagnostics (Basel)
Iancu DG, Cristescu L, Mares RG, Varga A, Tilea I.   +4 more
europepmc   +1 more source